Harrow Health (NASDAQ:HROW) Raised to “Buy” at ValuEngine

ValuEngine upgraded shares of Harrow Health (NASDAQ:HROW) from a hold rating to a buy rating in a report issued on Monday morning, ValuEngine reports.

HROW has been the subject of a number of other reports. Zacks Investment Research downgraded shares of Harrow Health from a hold rating to a sell rating in a report on Wednesday, March 13th. TheStreet raised shares of Harrow Health from a d- rating to a c rating in a report on Wednesday, May 1st.

NASDAQ HROW opened at $7.72 on Monday. Harrow Health has a 52-week low of $1.99 and a 52-week high of $8.05. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.43 and a quick ratio of 3.22. The company has a market cap of $187.01 million, a P/E ratio of 12.66 and a beta of -0.28. The stock’s fifty day moving average is $6.03.

Harrow Health (NASDAQ:HROW) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.14). Harrow Health had a return on equity of 100.84% and a net margin of 65.84%. The company had revenue of $12.29 million for the quarter, compared to the consensus estimate of $12.10 million. As a group, sell-side analysts predict that Harrow Health will post -0.1 earnings per share for the current fiscal year.

In other news, Director Robert J. Kammer sold 10,000 shares of Harrow Health stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $4.57, for a total transaction of $45,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 30,000 shares of company stock valued at $151,200 over the last ninety days. 12.43% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of HROW. Marshall Wace LLP bought a new stake in Harrow Health in the first quarter valued at about $1,104,000. Granite Investment Partners LLC bought a new stake in Harrow Health in the first quarter valued at about $1,254,000. Institutional & Family Asset Management LLC bought a new stake in shares of Harrow Health in the first quarter worth about $195,000. EAM Global Investors LLC bought a new stake in shares of Harrow Health in the first quarter worth about $171,000. Finally, Alambic Investment Management L.P. bought a new stake in shares of Harrow Health in the first quarter worth about $252,000. 32.14% of the stock is owned by institutional investors.

About Harrow Health

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Further Reading: Why are analyst ratings important in trading stocks?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.